P/B
—
Adial Pharmaceuticals
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
$8.2M
Market Cap • 10/15/2026
2010
(16 years)
Founded
2018
(8 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
—
EPS
—
Market Cap
Market Cap
8,2M
EV
18,1M
EV/Revenue
0
EV/EBITDA
-0,3
EV/EBIT
-0,3
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-377,1%
Total Yield
-377,1%
Payout
0%
Retained Earnings
-144M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
0%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
29,1%
CAGR Net Income 5Y
29,2%
CAGR EPS 5Y
-52,6%
CAGR OCF 5Y
0,5%
Leverage
N.D./EBITDA
0,5
Debt/Equity
0%
Current Ratio
5,6
Quick Ratio
5,6
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!